R%7ED leaders from the pharmaceutical and biotech industry, who recently participated in a roundtable discussion hosted by Tufts CSDD, said that well-structured collaborative agreements, in which the parties agree to share risks and rewards, can increase the possibility that a new medicine, which otherwise might not get to market, wins regulatory approval -- and at lower cost.
"The significance of these relationships involving drug sponsors, developers, and external service providers is that they become stakeholders in each other's business -- not just customers and vendors -- who stand to gain, or lose, together," said Tufts CSDD Director Kenneth I Kaitin.
According to Tufts CSDD, more than half of all new drugs approved in
Other points discussed at the roundtable, summarized in the August Tufts CSDD R%7ED Management Report, released today, include the following:
• Risk-sharing partnerships are most likely to succeed when governed by a charter that ensures executive engagement, clearly delineates roles and tasks for each organization and key individuals, and defines success metrics and quality measures.
• Large pharmaceutical companies are increasingly creating stand-alone entities that can access corporate resources while retaining the flexibility to partner with external early-stage development companies.
• Pre-competitive alliances, outside of relationships between a single drug sponsor and a contract research organization, which have increased nine-fold during the last decade, will likely continue to increase in number because they help set and proliferate standards and reduce redundancy.
Most Popular Stories
- Businesses, Investors Pressing for Green Policy
- E-scrap Recyclers Find Profits in Upgrades
- Congress Casts a Coy Vote on ISIS War
- Lower Used-Car Prices Roil the Auto Industry
- At Groupon, Not a Good Deal of Workplace Diversity
- 'The Voice' Sounds Different This Season
- Utah Hosts US Hispanic Chamber of Commerce Meeting
- Porn Lovers Get a New Search Engine
- Liberty Power Helps USHCC Go Green
- Investors Fret Yahoo's Future, Stock Dips